Measles: Old Vaccines, New Vaccines

Griffin, Diane E.; Pan, Chu-Hsiang

doi:10.1007/978-3-540-70617-5_10

Cited by 46 publications

(50 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The standard route of MV vaccination in humans is subcutaneous injection, but the vaccine can also effectively be administered i.m. (36)(37)(38). The skin of macaques is much more loosely connected to the subcutus than the skin of humans, and so to avoid redistribution of the vaccine over a large surface area, which would restrict finding and characterizing the target cells, we chose to use i.m.…”

Section: Fig 3 Target Cells Of Rmv Ez Egfp(3) Egfp Distribution In Mmentioning

confidence: 99%

Live-Attenuated Measles Virus Vaccine Targets Dendritic Cells and Macrophages in Muscle of Nonhuman Primates

Rennick

Vries

Carsillo

et al. 2015

J Virol

View full text Add to dashboard Cite

Although live-attenuated measles virus (MV) vaccines have been used successfully for over 50 years, the target cells that sustain virus replication in vivo are still unknown. We generated a reverse genetics system for the live-attenuated MV vaccine strain Edmonston-Zagreb ( IMPORTANCE Even though MV strain Edmonston-Zagreb has long been used as a live-attenuated vaccine (LAV) to protect against measles, nothing is known about the primary cells in which the virus replicates in vivo.This is vital information given the push to move toward needle-free routes of vaccination, since vaccine virus replication is essential for vaccination efficacy. We have generated a number of recombinant MV strains expressing enhanced green fluorescent protein. The virus that best mimicked the nonrecombinant vaccine virus was formulated according to protocols for production of commercial vaccine virus batches, and was subsequently used to assess viral tropism in nonhuman primates. The virus primarily replicated in professional antigen-presenting cells, which may explain why this LAV is so immunogenic and efficacious.

show abstract

Section: Fig 3 Target Cells Of Rmv Ez Egfp(3) Egfp Distribution In Mmentioning

confidence: 99%

Live-Attenuated Measles Virus Vaccine Targets Dendritic Cells and Macrophages in Muscle of Nonhuman Primates

Rennick

Vries

Carsillo

et al. 2015

J Virol

View full text Add to dashboard Cite

show abstract

“…An extensive safety record has been established for the use of vaccine strains of MeV in humans. 69 Most (pre) clinical research with oncolytic MeVs have used the attenuated vaccine Edmonston strain, which is perceived to be very safe in terms of toxicity. 70 The cancer selectivity of MeV stems from overexpression of the MeV receptor CD46 on malignant cells.…”

Section: Family Herpesviridae: Herpes Simplex Virus 1 (Hsv)mentioning

confidence: 99%

“…[72][73][74] Although wildtype MeV can cause potentially serious disease, attenuated MeV vaccine strains like Edmonston have an excellent safety record. 69 In clinical trials with rMeV-CEA, no evidence was seen of shedding in sputum and urine samples of patients who were intraperitoneally injected. 73 Spread of oncolytic MeV in the general population is highly unlikely since most individuals in industrialized countries are immunized, although herd immunity is currently waning with declining vaccination percentages.…”

Section: Family Herpesviridae: Herpes Simplex Virus 1 (Hsv)mentioning

confidence: 99%

Oncolytic viruses: From bench to bedside with a focus on safety

Buijs

Verhagen

Eijck

et al. 2015

Human Vaccines & Immunotherapeutics

115

105

View full text Add to dashboard Cite

“…DNA vaccines have these characteristics and theoretically could elicit antibody in the presence of passively acquired maternal antibody and be delivered at birth. Macaques provide an excellent nonhuman primate model for study of measles pathogenesis and vaccine-induced protective immunity (15)(16)(17)(18)(19)(20), and they have been used to test a number of different formulations of measles DNA vaccines (21,22). In general, these studies have demonstrated that naked DNA vaccines encoding the MeV glycoproteins hemagglutinin (H) and/or fusion (F), with and without the nucleoprotein (N), prime humoral and cellular immune responses associated with complete or partial protection from rash and viremia after challenge in juvenile macaques (23)(24)(25)(26).…”

mentioning

confidence: 99%

Poor Immune Responses of Newborn Rhesus Macaques to Measles Virus DNA Vaccines Expressing the Hemagglutinin and Fusion Glycoproteins

Polack

Lydy

Lee

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

A vaccine that would protect young infants against measles could facilitate elimination efforts and decrease morbidity and mortality in developing countries. However, immaturity of the immune system is an important obstacle to the development of such a vaccine. In this study, DNA vaccines expressing the measles virus (MeV) hemagglutinin (H) protein or H and fusion (F) proteins, previously shown to protect juvenile macaques, were used to immunize groups of 4 newborn rhesus macaques. Monkeys were inoculated intradermally with 200 g of each DNA at birth and at 10 months of age. As controls, 2 newborn macaques were similarly vaccinated with DNA encoding the influenza virus H5, and 4 received one dose of the current live attenuated MeV vaccine (LAV) intramuscularly. All monkeys were monitored for development of MeV-specific neutralizing and binding IgG antibody and cytotoxic T lymphocyte (CTL) responses. These responses were poor compared to the responses induced by LAV. At 18 months of age, all monkeys were challenged intratracheally with a wild-type strain of MeV. Monkeys that received the DNA vaccine encoding H and F, but not H alone, were primed for an MeV-specific CD8 ؉ CTL response but not for production of antibody. LAV-vaccinated monkeys were protected from rash and viremia, while DNA-vaccinated monkeys developed rashes, similar to control monkeys, but had 10-fold lower levels of viremia. We conclude that vaccination of infant macaques with DNA encoding MeV H and F provided only partial protection from MeV infection.

show abstract

Measles: Old Vaccines, New Vaccines

Cited by 46 publications

References 153 publications

Live-Attenuated Measles Virus Vaccine Targets Dendritic Cells and Macrophages in Muscle of Nonhuman Primates

Live-Attenuated Measles Virus Vaccine Targets Dendritic Cells and Macrophages in Muscle of Nonhuman Primates

Oncolytic viruses: From bench to bedside with a focus on safety

Poor Immune Responses of Newborn Rhesus Macaques to Measles Virus DNA Vaccines Expressing the Hemagglutinin and Fusion Glycoproteins

Contact Info

Product

Resources

About